TD Cowen analyst Ritu Baral has maintained their bullish stance on GHRS stock, giving a Buy rating today.
Ritu Baral has given her Buy rating due to a combination of factors including GH Research’s promising clinical trial results and strong financial position. The company recently released impressive data from its Phase 2b trial for GH001, which demonstrated significant efficacy in treating treatment-resistant depression, with a notable reduction in MADRS scores and a high percentage of patients achieving remission.
Furthermore, GH Research has a substantial cash reserve of $315 million, which is expected to sustain operations into 2026, providing a solid financial runway. The ongoing efforts to lift the clinical hold on their proprietary aerosol device and the anticipated updates on their Phase 3 program also contribute to the positive outlook. These elements collectively underpin Ritu Baral’s confidence in the company’s future prospects, justifying the Buy rating.
In another report released today, Guggenheim also maintained a Buy rating on the stock with a $29.00 price target.